Jan 28 (Reuters) - Regeneron Pharmaceuticals Inc and its partner Sanofi said on Friday they voluntarily withdrew their application with the U.S. health regulator for additional use of anti-cancer drug Libtayo as second-line treatment for patients with advanced cervical cancer. (Reporting by Leroy Leo; Editing by Shinjini Ganguli)
Our Standards: The Thomson Reuters Trust Principles.
